Phio Pharmaceuticals (PHIO) Enterprise Value (2016 - 2021)
Phio Pharmaceuticals' Enterprise Value history spans 10 years, with the latest figure at -$26.5 million for Q3 2021.
- For Q3 2021, Enterprise Value fell 56.81% year-over-year to -$26.5 million; the TTM value through Sep 2021 reached -$26.5 million, down 56.81%, while the annual FY2020 figure was -$14.2 million, 103.95% down from the prior year.
- Enterprise Value reached -$26.5 million in Q3 2021 per PHIO's latest filing, up from -$29.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.7 million in Q1 2018 to a low of -$32.7 million in Q1 2021.
- Average Enterprise Value over 5 years is -$12.9 million, with a median of -$10.9 million recorded in 2019.
- Peak YoY movement for Enterprise Value: surged 73.97% in 2018, then plummeted 381.78% in 2019.
- A 5-year view of Enterprise Value shows it stood at -$3.6 million in 2017, then plummeted by 311.15% to -$14.9 million in 2018, then soared by 53.22% to -$7.0 million in 2019, then tumbled by 103.95% to -$14.2 million in 2020, then plummeted by 86.25% to -$26.5 million in 2021.
- Per Business Quant, the three most recent readings for PHIO's Enterprise Value are -$26.5 million (Q3 2021), -$29.4 million (Q2 2021), and -$32.7 million (Q1 2021).